Global Alzheimer’s Therapeutic Market Size By Product Type (Cholinesterase inhibitors, Biomarkers), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Geographic Scope And Forecast

Alzheimer’s Therapeutic Market Size And Forecast

Alzheimer’s Therapeutic Market size was valued at USD 3.76 Billion in 2021 and is projected to reach USD 12.8 Billion by 2030, growing at a CAGR of 12.1% from 2022 to 2030.

The increasing prevalence of Alzheimer’s disease, rising health awareness among people about the same, and the introduction of novel technologies and drugs to improve life expectancy are driving the growth of the Global Alzheimer’s Therapeutic market significantly. The Global Alzheimer’s Therapeutic Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Alzheimer’s Therapeutic Market Definition

Alzheimer’s disease is a neurodegenerative disorder that typically develops in middle age and is one of the leading causes of dementia. Dementia is defined as cognitive decline and other intellectual capacities that are severe enough to interfere with daily life. Alzheimer’s disease worsens over time. Alzheimer’s is a devastating disease whereas dementia symptoms accumulate over time. Cognitive decline is mild in the early stages of Alzheimer’s disease however, by the late stages, people lose the ability to carry on a conversation and respond to their condition. Memory loss, repetitive movements, insomnia, anxiety, depression, agitation, and loss of reasoning abilities are some of the signs and symptoms of Alzheimer’s disease.

Despite the fact that Alzheimer’s medications cannot prevent the disease from progressing, they can slow the decline of dementia side effects and improve personal satisfaction for those suffering from Alzheimer’s. Individuals over the age of 65 are more likely to develop Alzheimer’s disease. According to Alzheimer’s disease raw numbers, it is estimated that another instance of AD occurs at regular intervals, with an extremely high prevalence of nearly 35 million patients worldwide. As result, clinical diagnostics and therapeutics for Alzheimer’s disease and other neurodegenerative diseases are improving significantly. The clinical diagnosis of Alzheimer’s disease is incorrect in about 10% to 15% of cases. To overcome this barrier, specific biomarkers are used, which improve the accuracy of the finding.

Global Alzheimer’s Therapeutic Market Overview

The market overview section of this report mainly consists of the basic dynamics of the market which include drivers, restraints, opportunities, and challenges faced by the industry. The Global Alzheimer’s Therapeutic Market report provides an outlook on the development of the market in terms of revenue throughout the prognosis period. The Global Alzheimer’s Therapeutic Market is expected to experience remarkable growth in the upcoming years owing to the increasing demand for minimally invasive procedures in the treatment of Alzheimer’s disease. The increasing incidence and prevalence of Alzheimer’s disease, rising health awareness among people about this disease, and the introduction of novel technologies and drugs to improve life expectancy are fueling the growth of the Global Alzheimer’s Therapeutic market significantly.

Additionally, technological advancements for the development of innovative drugs and techniques in the treatment of Alzheimer’s disease and increasing investment in R&D activities are also promoting the market growth. Furthermore, the rise in the geriatric population across the globe, growth in the healthcare sector, and increasing government initiatives and support in the form of funds and grants to improve diagnostic techniques and treatment procedures, also boost the growth of the Alzheimer’s Therapeutic market.

Moreover, an increase in the patient population of Alzheimer’s disease, increased product development, and launch activities and growth potential in developing nations is expected to provide profitable growth opportunities to the market players in the Global Alzheimer’s Therapeutic market during the forecast period. However, late-stage drug failures, a lack of surrogate markers for drug discovery and drug development, insufficient research funding, and lengthy uncertain processes are expected to hinder the growth of the Global Alzheimer’s Therapeutic Market over the forecast period.

Global Alzheimer’s Therapeutic Market Segmentation Analysis

The Global Alzheimer’s Therapeutic Market is segmented on the basis of Product Type, Distribution Channel, and Geography.

Alzheimer’s Therapeutic Market, Product Type

• Cholinesterase inhibitors• N-Methyl-D-Aspartate (NMDA) receptor antagonist• Biomarkers• Others

Based on Product Type, the market is segmented into Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, Biomarkers, and Others. the cholinesterase inhibitors segment accounts for the highest revenue share of the Global Alzheimer’s Therapeutics Market in 2020 and is expected to dominate the market over the forecast period as they are commonly used to treat symptoms associated with memory, thinking, language, judgment, and other thought processes by healthcare professionals. This is driving the market

Alzheimer’s Therapeutic Market, By Distribution Channel

• Hospital Pharmacy• Retail Pharmacy• Online Pharmacy

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy on the basis of Distribution Channel. Due to the increasing use of online pharmacy apps or websites from the comfort of home among customers, especially during the COVID-19 pandemic due to sudden lockdown and quarantine restrictions, the online pharmacy segment is expected to hold the largest revenue share of the Global Alzheimer’s Therapeutic market during the forecast period. This has further fueled the market growth of this segment.

Alzheimer’s Therapeutic Market, By Geography

• North America• Europe• Asia Pacific• Rest of the World

On the basis of Geography, the Global Alzheimer’s Therapeutic Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in Global Alzheimer’s Therapeutic Market in 2020 and is expected to retain its dominance throughout the forecast period. The revenue growth in the North American market is mainly attributed to the increased investment in R&D activities for the development of technologically advanced techniques and innovative drugs in the treatment of Alzheimer’s disease.

Additionally, the increasing geriatric population, rising incidence, and prevalence of Alzheimer’s disease, rising healthcare sectors, presence of skilled professionals, and wide availability of technologically advanced Alzheimer’s Therapeutic are the major factors that boost the Alzheimer’s Therapeutic market in the region. The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to the increasing focus on the development of healthcare infrastructure and rising prevalence of Alzheimer’s disease in the developing nations such as China, and India in this region.

Key Players

The “Global Alzheimer’s Therapeutic Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H. Lundbeck A/S, AC Immune, TauRx Pharmaceuticals Ltd., Actavis plc., Forest Laboratories, Teva Pharmaceuticals Industries Ltd., Janssen Pharmaceutical, GE Healthcare, Eli Lilly and Company, DiaGenic ASA, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca, and Daiichi Sankyo Company Ltd., and among others. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In November 2021, Brigham and Women’s Hospital in Boston, USA began a clinical trial to test the safety and efficacy of a new nasal vaccine for Alzheimer’s disease.

• In October 2021, Salk Institute started a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to check its safety in humans.

• In August 2019, Oxford Brain Diagnostics (an Oxford University spinoff) was founded to provide a new method for diagnosing Alzheimer’s disease from MRI scans.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.